on EnVVeno Medical Corporation (NASDAQ:NVNO)
EnVVeno Medical's VenoValve to be Highlighted at SCVS Symposium
enVVeno Medical Corporation (NASDAQ: NVNO) announced that its abstract on the VenoValve® has been accepted for presentation at the Society for Clinical Vascular Surgery (SCVS) 52nd Annual Symposium, held in Austin, TX. Dr. Cassius Iyad Ochoa Chaar of Yale School of Medicine will present findings on April 2, 2025.
The VenoValve® is a surgical replacement for patients with severe deep venous chronic venous insufficiency (CVI). enVVeno estimates 2.5 million potential new patients annually in the U.S. The company has submitted a pre-market authorization application to the FDA, with a decision expected in late 2025.
CVI, often caused by blood clots, leads to leg swelling, pain, and even venous ulcers, impacting daily life. No effective treatments currently exist, and CVI costs the U.S. healthcare system over $4 billion annually.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all EnVVeno Medical Corporation news